AbbVie Net Income From Continuing Ops from 2010 to 2025

ABBV Stock  USD 210.01  1.95  0.92%   
AbbVie Net Income From Continuing Ops yearly trend continues to be fairly stable with very little volatility. Net Income From Continuing Ops is likely to outpace its year average in 2025. During the period from 2010 to 2025, AbbVie Net Income From Continuing Ops regression line of quarterly data had mean square error of 5767064.2 T and geometric mean of  5,248,892,696. View All Fundamentals
 
Net Income From Continuing Ops  
First Reported
2010-12-31
Previous Quarter
1.6 B
Current Value
-23 M
Quarterly Volatility
1.3 B
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check AbbVie financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AbbVie's main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.8 B, Interest Expense of 2.9 B or Selling General Administrative of 8.3 B, as well as many indicators such as Price To Sales Ratio of 3.46, Dividend Yield of 0.0288 or PTB Ratio of 99.06. AbbVie financial statements analysis is a perfect complement when working with AbbVie Valuation or Volatility modules.
  
Check out the analysis of AbbVie Correlation against competitors.

Latest AbbVie's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of AbbVie Inc over the last few years. It is AbbVie's Net Income From Continuing Ops historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AbbVie's overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

AbbVie Net Income From Continuing Ops Regression Statistics

Arithmetic Mean5,758,277,083
Geometric Mean5,248,892,696
Coefficient Of Variation46.46
Mean Deviation1,891,755,990
Median5,144,000,000
Standard Deviation2,675,086,365
Sample Variance7156087.1T
Range10.1B
R-Value0.50
Mean Square Error5767064.2T
R-Squared0.25
Significance0.05
Slope279,718,382
Total Sum of Squares107341305.9T

AbbVie Net Income From Continuing Ops History

20256.7 B
20244.3 B
20234.9 B
202211.8 B
202111.5 B
20204.6 B
20197.9 B

About AbbVie Financial Statements

AbbVie investors use historical fundamental indicators, such as AbbVie's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in AbbVie. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Income From Continuing Ops4.3 B6.7 B

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for AbbVie Stock Analysis

When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.